Therapeutic compositions of undecylenic acid and arginine
Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.
1. A composition comprising, as a therapeutic complex, a mixture of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine having a molar ratio of between 1:0.6 to 1:1.6, wherein the composition is free of Rhein.
2. The composition of claim 1 , wherein the mixture of undecylenic acid:Arginine comprises a mixture of undecylenic acid:L-Arginine.
3. The composition of claim 1 , wherein the composition comprises at least 0.001% w/w of the complex of undecylenic acid and Arginine.
4. The composition of claim 1 , wherein the molar ratio of undecylenic acid:Arginine is between 1:0.6 to 1:1.2.
5. The composition of claim 1 , wherein the molar ratio of undecylenic acid:Arginine is in a 1:1 molar ratio.
6. The composition of claim 1 , wherein the composition is free of cetyl alcohol.
7. The composition of claim 1 , wherein the composition is an aqueous composition.
8. The composition of claim 1 , further comprising an excipient, diluent, carrier or fragrance.
9. The composition of claim 8 , wherein said excipient, diluent, carrier or fragrance is suitable for topical application or for use on surfaces.
10. The composition of claim 1 , wherein the composition is configured as a liquid, emulsion, solution, ointment or cream in a form suitable for topical administration to a human or for use on surfaces.
11. The composition of claim 1 , wherein the composition is configured for one or more of: oral, parenteral, intraperitoneal, transmucosal, transdermal, rectal, inhalable, and topical administration.
12. The composition of claim 1 , wherein the composition is configured for administration as a hand sanitizer, surface sanitizer or disinfectant.
13. The composition of claim 1 , further comprising benzalkonium chloride.
14. A composition comprising an aqueous solution of a mixture of undecylenic acid: L-Arginine forming a therapeutic complex and having a molar ratio of undecylenic acid: L-Arginine of between 1:0.6 to 1:1.6 at a total concentration of at least 0.001% w/w, wherein the composition is free of Rhein.
15. The composition of claim 14 , wherein the molar ratio of undecylenic acid: L-Arginine is between 1:0.6 to 1:1.2.
16. The composition of claim 14 , wherein the molar ratio of undecylenic acid: L-Arginine is in a 1:1 molar ratio.
17. The composition of claim 14 , further comprising an excipient, diluent, carrier or fragrance.
18. The composition of claim 17 , wherein said excipient, diluent, carrier or fragrance is suitable for topical application or for use on surfaces.
19. The composition of claim 14 , wherein the composition is configured as a liquid, emulsion, solution, ointment or cream in a form suitable for topical administration to a human or for use on surfaces.
20. The composition of claim 14 , wherein the composition is configured for one or more of: oral, parenteral, intraperitoneal, transmucosal, transdermal, rectal, inhalable, and topical administration.
21. The composition of claim 14 , further comprising benzalkonium chloride.
22. The composition of claim 14 , wherein the composition is configured for administration as a hand sanitizer, surface sanitizer or disinfectant.
23. A method of treating a patient for one or more of Staphylococcus aureus, Escherichia coli, Kebsiella pneumoniae, Pseudomonas aeruginosa , Herpes simplex viruses, Ebola, Human Rhinovirus-14, SARS Coronavirus, Dengue virus and Yellow Fever virus in need thereof, the method comprising: administering to said patient a therapeutically effective amount of a composition comprising an aqueous solution of a complex of undecylenic acid: L-Arginine in a molar ratio of between 1:0.6 to 1:1.6 wherein the total concentration of undecylenic acid: L-Arginine in the composition is at least 0.001% w/w.
24. The method of claim 23 , wherein the molar ratio of undecylenic acid: L-Arginine is in an approximately 1:1 molar ratio.
25. The method of claim 23 , wherein administering comprises is applying the composition to the patient's skin.
26. The method of claim 23 , wherein the patient has a cancer.
27. The method of claim 26 , wherein the cancer is a skin cancer.
28. A method of treating a patient for one or more of glioma cell cancer, melanoma, leukemia, lung cancer, prostate cancer, or breast cancer, the method comprising: administering to said patient a therapeutically effective amount of a composition comprising an aqueous solution of a complex of undecylenic acid: L-Arginine in a molar ratio of between 1:0.6 to 1:1.6 wherein the total concentration of undecylenic acid: L-Arginine in the composition is at least 0.001% w/w.